NCT02722941View on ClinicalTrials.gov

Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 10, 2016

Primary Completion Date

June 7, 2020

Study Completion Date

January 18, 2021

Conditions
Multiple Myeloma
Interventions
DRUG

Panobinostat

Maintenance therapy dosing as outlined in Cohorts A and B.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER